You are here

Article Text

Article menu
Download PDFPDF
Correspondence
COVID-19 infection in a patient with FMF: does colchicine have a protective effect?
  1. Senol Kobak
  1. Rheumatology, Istinye University, Istanbul, Turkey
  1. Correspondence to Professor Senol Kobak, Rheumatology, Istinye University, Istanbul, Turkey; senolkobak{at}yahoo.com

https://doi.org/10.1136/annrheumdis-2020-217882

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with great interest the report by Monti et al on the 320 rheumatic patients treated with various disease-modifying anti-rheumatic drugs (DMARDs) in the era of COVID-19 infection.1 They suggest that patients with chronic arthritis receiving DMARDs may not have an increased risk of severe COVID-19. We agree that patients under DMARD treatment should be closely monitored since data are lacking. Also, we hypothesise that some DMARDs (especially colchicine) may protect rheumatic patients from COVID-19 or perhaps cause them to pass in a milder form of the disease. COVID-19 is not just a simple viral infection; it is an autoinflammatory/autoimmune process that develops as a result of immune system dysfunction, cytokine release syndrome and haemophagocytic lymphohistiocytosis.2 Herein we reported COVID-19 infection in a patient with familial Mediterranean fever (FMF) under treatment with colchicine.

    A 36-year-old …

    View Full Text

    Footnotes

    • Contributors None.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Patient consent for publication Obtained.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles